Global Bladder Disorders Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143124
- Pages: 225
-
Format:
Short Description
Global Bladder Disorders Market- By Type (Cystitis, Urinary Incontinence, Overactive Bladder, Interstitial Cystitis, Bladder Cancer), Treatment Type (Surgery, Medication, Non-surgical, and others), End User (Hospitals, Clinics, Ambulatory Surgery Centres, Others), Distribution Channel (Direct, Retail) Country (U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippine, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of the Middle East and Africa) Industry Trends and Forecast to 2029
Market Definition:
Bladder-related disorders include Cystitis - inflammation of the bladder, often from infection, Urinary incontinence - loss of bladder control, Overactive bladder - a condition in which the bladder squeezes urine out at the wrong time, Interstitial cystitis - a chronic problem that causes bladder pain and frequent, urgent urination and bladder cancer.
The doctors perform different tests to diagnose the bladder disorder, including x-rays, urine tests, and a bladder wall examination by scope called a cystoscope. The treatment of the disorder depends on the cause of the problem, including medication, surgeries (in severe cases), and non-surgical procedures.
Anticholinergic medications are the first line of pharmacotherapy for Over-active Bladder (OAB) syndrome. OAB is a clinical symptom characterized by the urgency of the desire to pass urine, which is difficult to defer. Generally, the frequency of passing urine more than eight times per day is considered in OAB. Anticholinergic drugs inhibit the muscarinic receptors at the detrusor muscle, reducing bladder contractility. To reduce the side effects, new medications with improved bladder selectivity and extended-release formulations are being developed. The majority of the more recent medications are equally effective at reducing the symptoms of an overactive bladder.
Market Segmentation:
The global bladder disorders market is categorized into four segments: type, treatment type, end user, and distribution channel.
On the basis of type, the global bladder disorders market is segmented into Cystitis, Urinary Incontinence, Overactive Bladder, Interstitial Cystitis, Bladder Cancer
On the basis of treatment type, the global bladder disorders market is segmented into Surgery, Medication, Non-surgical, and others
On the basis of end-user, the global bladder disorders market is segmented into Hospitals, Clinics, Ambulatory Surgery Centres, Others
On the basis of distribution channel, the global bladder disorders market is segmented into direct and retail
Market Players
The major companies which are dealing in the global bladder disorders market are listed below:
Medtronic
Laborie
Boston Scientific Corporation
Pfizer Inc.
Astellas Pharma Inc.
KYORIN Pharmaceutical Co., Ltd. (A subsidiary of KYORIN Holdings, Inc.)
Bristol-Myers Squibb Company
Johnson & Johnson Services, Inc.
Axonics, Inc.
Merck & Co., Inc.
Viatris Inc.
Blue Wind Medical
Valencia Technologies
Gaylord Chemical Company, L.L.C.
Coloplast Corp, AbbVie Inc.
Sun Pharmaceutical Industries Ltd.
Zydus Group
Swati Spentose
Urovant Sciences, among others.
TABLE OF CONTENTS
1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF GLOBAL BLADDER DISORDERS MARKET 24
1.4 LIMITATIONS 25
1.5 MARKETS COVERED 26
2 MARKET SEGMENTATION 28
2.1 MARKETS COVERED 28
2.2 GEOGRAPHICAL SCOPE 29
2.3 YEARS CONSIDERED FOR THE STUDY 30
2.4 CURRENCY AND PRICING 30
2.5 DBMR TRIPOD DATA VALIDATION MODEL 31
2.6 MULTIVARIATE MODELLING 34
2.7 TYPE LIFELINE CURVE 34
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
2.9 DBMR MARKET POSITION GRID 36
2.10 MARKET END USER COVERAGE GRID 37
2.11 VENDOR SHARE ANALYSIS 38
2.12 SECONDARY SOURCES 39
2.13 ASSUMPTIONS 39
3 EXECUTIVE SUMMARY 40
4 PREMIUM INSIGHTS 42
4.1 PESTEL ANALYSIS 45
4.2 PORTER'S FIVE FORCES 46
4.3 GLOBAL BLADDER DISORDERS MARKET, PIPELINE ANALYSIS 47
5 GLOBAL BLADDER DISORDER MARKET: REGULATIONS 48
5.1 THE U.S. REGULATORY FRAMEWORK FOR BLADDER DISOREDER MEDICATION 48
5.2 EUROPE REGULATORY FRAMEWORK FOR BLADDER DISORDER DRUGS 48
5.3 JAPAN REGULATORY GUIDANCE ON BLADDER DISORDER DRUGS 49
6 GLOBAL BLADDER DISORDERS MARKET OVERVIEW 51
6.1 DRIVERS 53
6.1.1 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS 53
6.1.2 GROWING GERIATRIC POPULATION 53
6.1.3 RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS 54
6.1.4 COMBINATION OF DIFFERENT TARGET THERAPIES 54
6.2 RESTRAINTS 55
6.2.1 HIGH COST ASSOCIATED WITH BLADDER DISORDER DIAGNOSTIC TREATMENT 55
6.2.2 PRODUCTS RECALLS FROM MARKET 55
6.3 OPPORTUNITIES 55
6.3.1 SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS 55
6.3.2 RISING DISEASE MANAGEMENT PROGRAMS 56
6.4 CHALLENGES 57
6.4.1 LACK OF AWARENESS ABOUT BLADDER DISORDERS RELATED PROBLEMS 57
6.4.2 PATENT EXPIRY OF DRUGS 57
7 GLOBAL BLADDER DISORDERS MARKET, BY TYPE 59
7.1 OVERVIEW 60
7.2 OVERACTIVE BLADDER 63
7.3 URINARY INCONTINENCE 63
7.4 CYSTITIS 64
7.5 INTERSTITIAL CYSTITIS 65
7.6 BLADDER CANCER 66
7.7 OTHERS 67
8 GLOBAL BLADDER DISORDERS MARKET, BY TREATMENT TYPE 68
8.1 OVERVIEW 69
8.2 MEDICATION 72
8.2.1 TOLTERODINE 73
8.2.2 MIRABEGRON 73
8.2.3 FESOTERODINE 73
8.2.4 OXYBUTYNIN 73
8.2.5 SOLIFENACIN 73
8.2.6 DARIFENACIN 73
8.2.7 TROSPIUM 73
8.2.8 OTHERS 74
8.3 SURGERY 74
8.3.1 SURGERY TO INCREASE BLADDER CAPACITY 75
8.3.2 BLADDER REMOVAL 75
8.3.3 OTHERS 75
8.4 OTHERS 75
9 GLOBAL BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL 77
9.1 OVERVIEW 78
9.2 DIRECT 81
9.3 RETAIL 81
10 GLOBAL BLADDER DISORDERS MARKET, BY END USER 83
10.1 OVERVIEW 84
10.2 HOSPITALS 87
10.3 CLINICS 88
10.4 AMBULATORY SURGICAL CENTERS 88
10.5 OTHERS 89
11 GLOBAL BLADDER DISORDERS MARKET, BY GEOGRAPHY 91
11.1 OVERVIEW 92
11.2 NORTH AMERICA 97
11.2.1 U.S. 104
11.2.2 CANADA 106
11.2.3 MEXICO 108
11.3 EUROPE 110
11.3.1 GERMANY 117
11.3.2 U.K. 119
11.3.3 FRANCE 121
11.3.4 ITALY 123
11.3.5 SPAIN 125
11.3.6 TURKEY 127
11.3.7 RUSSIA 129
11.3.8 NETHERLANDS 131
11.3.9 SWITZERLAND 133
11.3.10 BELGIUM 135
11.3.11 REST OF EUROPE 137
11.4 ASIA-PACIFIC 138
11.4.1 CHINA 145
11.4.2 JAPAN 147
11.4.3 INDIA 149
11.4.4 AUSTRALIA 151
11.4.5 SOUTH KOREA 153
11.4.6 THAILAND 155
11.4.7 SINGAPORE 157
11.4.8 INDONESIA 159
11.4.9 MALAYSIA 161
11.4.10 VIETNAM 163
11.4.11 PHILIPPINES 165
11.4.12 REST OF ASIA-PACIFIC 167
11.5 SOUTH AMERICA 168
11.5.1 BRAZIL 175
11.5.2 ARGENTINA 177
11.5.3 REST OF SOUTH AMERICA 179
11.6 MIDDLE EAST AND AFRICA 180
11.6.1 SAUDI ARABIA 187
11.6.2 SOUTH AFRICA 189
11.6.3 UAE 191
11.6.4 EGYPT 193
11.6.5 ISRAEL 195
11.6.6 REST OF MIDDLE EAST AND AFRICA 197
12 GLOBAL BLADDER DISORDERS MARKET: COMPANY LANDSCAPE 198
12.1 COMPANY SHARE ANALYSIS: GLOBAL 198
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 199
12.3 COMPANY SHARE ANALYSIS: EUROPE 200
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 201
13 SWOT ANALYSIS 202
14 COMPANY PROFILE 203
14.1 MERCK AND CO. INC. (2021) 203
14.1.1 COMPANY SNAPSHOT 203
14.1.2 REVENUE ANALYSIS 203
14.1.3 COMPANY SHARE ANALYSIS 204
14.1.4 PRODUCT PORTFOLIO 204
14.1.5 RECENT DEVELOPMENT 204
14.2 ASTELLAS PHARMA INC. (2021) 205
14.2.1 COMPANY SNAPSHOT 205
14.2.2 REVENUE ANALYSIS 205
14.2.3 COMPANY SHARE ANALYSIS 206
14.2.4 PRODUCT PORTFOLIO 206
14.2.5 RECENT DEVELOPMENTS 206
14.3 BRISTOL-MYERS SQUIBB COMPANY (2021) 208
14.3.1 COMPANY SNAPSHOT 208
14.3.2 REVENUE ANALYSIS 208
14.3.3 COMPANY SHARE ANALYSIS 209
14.3.4 PRODUCT PORTFOLIO 209
14.3.5 RECENT DEVELOPMENT 209
14.4 BOSTON SCIENTIFIC CORPORATION (2021) 210
14.4.1 COMPANY SNAPSHOT 210
14.4.2 REVENUE ANALYSIS 210
14.4.3 COMPANY SHARE ANALYSIS 211
14.4.4 PRODUCT PORTFOLIO 211
14.4.5 RECENT DEVELOPMENT 211
14.5 VIATRIS INC. (2021) 212
14.5.1 COMPANY SNAPSHOT 212
14.5.2 REVENUE ANALYSIS 212
14.5.3 COMPANY SHARE ANALYSIS 213
14.5.4 PRODUCT PORTFOLIO 213
14.5.5 RECENT DEVELOPMENT 213
14.6 ABBVIE (2021) 214
14.6.1 COMPANY SNAPSHOT 214
14.6.2 REVENUE ANALYSIS 214
14.6.3 PRODUCT PORTFOLIO 215
14.6.4 RECENT DEVELOPMENT 215
14.7 AXONICS, INC. (2021) 216
14.7.1 COMPANY SNAPSHOT 216
14.7.2 REVENUE ANALYSIS 216
14.7.3 PRODUCT PORTFOLIO 216
14.7.4 RECENT DEVELOPMENT 217
14.8 BLUE WIND MEDICAL (2021) 218
14.8.1 COMPANY SNAPSHOT 218
14.8.2 PRODUCT PORTFOLIO 218
14.8.3 RECENT DEVELOPMENT 218
14.9 COLOPLAST CORP. (2021) 219
14.9.1 COMPANY SNAPSHOT 219
14.9.2 REVENUE ANALYSIS 219
14.9.3 PRODUCT PORTFOLIO 220
14.10 GAYLORD CHEMICAL COMPANY, LLC (2021) 221
14.10.1 COMPANY SNAPSHOT 221
14.10.2 PRODUCT PORTFOLIO 221
14.10.3 RECENT DEVELOPMENT 221
14.11 JOHNSON & JOHNSON SERVICES, INC. (2021) 222
14.11.1 COMPANY SNAPSHOT 222
14.11.2 REVENUE ANALYSIS 222
14.11.3 PRODUCT PORTFOLIO 223
14.11.4 RECENT DEVELOPMENT 223
14.12 KYORIN PHARMACEUTICAL CO., LTD. (A SUBSIDIARY OF KYORIN HOLDINGS, INC.) (2021) 224
14.12.1 COMPANY SNAPSHOT 224
14.12.2 PRODUCT PORTFOLIO 224
14.12.3 RECENT DEVELOPMENTS 225
14.13 LABORIE (2021) 226
14.13.1 COMPANY SNAPSHOT 226
14.13.2 PRODUCT PORTFOLIO 226
14.13.3 RECENT DEVELOPMENT 227
14.14 MEDTRONIC (2021) 228
14.14.1 COMPANY SNAPSHOT 228
14.14.2 REVENUE ANALYSIS 228
14.14.3 PRODUCT PORTFOLIO 229
14.14.4 RECENT DEVELOPMENTS 229
14.15 PFIZER INC. (2021) 230
14.15.1 COMPANY SNAPSHOT 230
14.15.2 REVENUE ANALYSIS 230
14.15.3 PRODUCT PORTFOLIO 231
14.15.4 RECENT DEVELOPMENTS 231
14.16 VALENCIA TECHNOLOGIES (2021) 232
14.16.1 COMPANY SNAPSHOT 232
14.16.2 PRODUCT PORTFOLIO 232
14.16.3 RECENT DEVELOPMENT 233
14.17 SUN PHAMACEUTICAL INDUSTRIES LTD. (2021) 234
14.17.1 COMPANY SNAPSHOT 234
14.17.2 REVENUE ANALYSIS 234
14.17.3 PRODUCT PORTFOLIO 235
14.17.4 RECENT DEVELOPMENT 235
14.18 SWATI SPENTOSE (2021) 236
14.18.1 COMPANY SNAPSHOT 236
14.18.2 PRODUCT PORTFOLIO 236
14.18.3 RECENT DEVELOPMENT 236
14.19 UROVANT SCIENCES (2021) 237
14.19.1 COMPANY SNAPSHOT 237
14.19.2 PRODUCT PORTFOLIO 237
14.19.3 RECENT DEVELOPMENT 237
14.20 ZYDUS GROUP (2021) 238
14.20.1 COMPANY SNAPSHOT 238
14.20.2 PRODUCT PORTFOLIO 238
14.20.3 RECENT DEVELOPMENT 238
15 QUESTIONNAIRE 239
16 RELATED REPORTS 242
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
